High-Risk Neuroblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
High-Risk Neuroblastoma Market Outlook
Thelansis’s “High-Risk Neuroblastoma
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential High-Risk Neuroblastoma treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
High-Risk Neuroblastoma Overview
Neuroblastoma
stands as the most prevalent cancer in children below the age of one and
constitutes the primary solid tumor found outside the central nervous system
across all age brackets. Its clinical behavior encompasses a wide range,
delineated into three risk groups: low, medium, and high. Approximately 50% of
neuroblastoma cases fall into the high-risk category, determined by age,
disease extent, histological findings, and cytogenetic characteristics such as
MYCN amplification and DNA ploidy. Notably, children over 18 months with
metastatic disease are classified as high-risk due to historically poor
outcomes in this subgroup. MYCN amplification also places patients in the
high-risk category, except those with L1 MYCN amplified disease undergoing complete
resection. The management of high-risk neuroblastoma poses significant
challenges and necessitates a comprehensive approach involving multiple
modalities.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment